The Global Immune Checkpoint Inhibitors Market size is projected to grow from $14 billion in 2021 with a CAGR of 19% during the forecast period from 2021-2028. The major factors driving growth in this market are the increasing prevalence of cancer and rising incidence rates for various types of cancer globally, coupled with the high efficacy and safety profile of these drugs thus giving rise to an urgent need to develop new treatments for cancer that can improve quality of life as well as patient survival rate.
Immune Checkpoint Inhibitors are drugs that block one of the brakes on our immune system. Immune checkpoints are special proteins located on a cell surface that can tell other cells whether to attack it or not. When these signals aren’t functioning correctly, cancer cells may escape the body's natural defenses and start growing out of control (progression). The drugs called "immune checkpoint inhibitors" target those checkpoints in order to help with this problem - they either stop them from being active at all or increase their activity so there is more opportunity for an attacking T-cell to bind onto them before anything else happens.
On the basis of Types, the market is segmented into PD-I/PD-Ll (Nivolumab, Opdivo), CTLA-IV (ipilimumab), and Others.
Nivolumab is a type of immune checkpoint inhibitor drug that blocks PD-Ll, which suppresses the activity of CD28 and CTLA-I. Opdivo also comes from this class of drugs and it targets both PD-Ll and PD-LI. It can be used to treat cancer by blocking these receptors on T cells so they are able to attack cancerous cells in the body more effectively. Nivolumab and Opdivo are used to treat cancer. They both interfere with T-cells, which can typically fight against the growth of cancerous cells in the body.
CTLA-IV (ipilimumab) can be defined as an immune checkpoint inhibitor. CTLA-IV (ipilimumab) is used to treat cancer and it can block the body's tumor defense system from working normally. It belongs to a group of medications called monoclonal antibodies, which are proteins that fight off diseases or viruses by sticking themselves onto them so they cannot work properly. The effects of this medication last for about two years on average but some people have had it as long as five years before their tumors came back more aggressively than before.
On the basis of Application, the market is segmented into Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, and Blood cancer.
Lung cancer is the leading cause of death worldwide. Immunotherapy has transformed the treatment landscape for patients with lung cancer by targeting tumor cells that are inaccessible to conventional therapies and immune system checkpoints. It binds to a protein on the surface of cancers (PD-L, CD80) and prevents it from stimulating an immune response against them. Immune checkpoint inhibitors have been found effective in non-small cell bronchial carcinomas as well as squamous cell lung carcinoma.
A phase III study showed a median overall survival time was significantly prolonged when immunotherapy was used alongside chemotherapy or radiotherapy therapy than chemo or radiation alone among metastatic NSCLC patients who had not received any previous treatments.
Immune checkpoint inhibitors are also applied in the treatment of colorectal cancer. In this case, it is used for patients who have metastatic disease or those with previously treated locally advanced disease that has come back. The drug can be given as a single agent, but more commonly is combined with other drugs such as chemotherapy and radiation therapy.
Immunotherapy may improve survival rates by up to two years when used after surgery to remove the colon (colectomy) and/or rectum (proctectomy). This form of immunotherapy might be recommended if there are no signs that the tumor has spread outside of these areas during an examination called panendoscopy. Immunotherapy could help prevent tumors from coming back even though they had not been removed surgically.
Immune checkpoint inhibitors are being used as a treatment option for cancer. In terms of breast cancer, they can be used in the following ways:
Injections (Ipilimumab) - Tumor vaccines and Gene Therapy – Immunotherapy associated with chemotherapy or targeted therapy
“Chemoimmunology” is an emerging field that aims to see how drugs can act on both sides of the tumor defense system at once—the immune response and DNA mutations.---There has been no definitive study yet about their efficacy against metastatic cancers. It's important to note these treatments should not replace standard therapies but rather work alongside them when appropriate medical management decisions have been made for each patient.
There are many uses for immune checkpoint inhibitors in prostate cancer. Immune checkpoint inhibitors have been shown to be effective on their own or combined with other medications, such as chemotherapy and radiation therapy before surgery, during radiotherapy after surgery if the tumor is too large for successful surgical removal without harming adjacent tissue structures, or following radical prostatectomy (removal of all visible parts of the tumor).
They may also work well to treat the metastatic disease which has spread throughout the body from a localized site but rarely used alone since it can result in an increase in resistance over time. In addition, they can prevent recurrence by slowing down the growth rates of residual cells that managed to survive treatment regimens.
Immune checkpoint inhibitors work in melanoma by ensuring that the T-cells can detect and destroy cancer cells. They do this by blocking a protein called Programmed cell death Protein (PD-L) or cytotoxic T lymphocyte antigen (CTLA)-associated protein A(APA). Blocking PD-L or CTLA function has been shown to be more effective at inducing an immune response than other therapies, such as chemotherapy.
Immune Checkpoint Inhibitors are used for the treatment of blood cancer. It can be combined with other treatments such as chemotherapy or radiotherapy to treat blood cancers like leukemia, lymphoma, and myelomas. CTLA-123 is a drug that inhibits CTLA-270 at the T cell level. It has been shown that this specific type of therapy may have promising results in patients with non-Hodgkin's B cell lymphoma (NHL).
On the basis of Region, the market is segmented into North America, Europe, Asia Pacific, and the Middle East. The European market is expected to be the largest market for Immune Checkpoint Inhibitors. The Asia Pacific market will grow at a high CAGR during 2021-2028, owing to an increase in investments and new product launches in China and India.
Up Market Research published a new report titled “Immune Checkpoint Inhibitors Market research report which is segmented by Types (PD-1/PD-L1, CTLA-4), By Applications (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, Other), By Players/Companies Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, NewLink Genetics, ArGEN-X, Seattle Genetics, Pfizer, MacroGenics, Celldex Therapeutics, CureTech, Immutep, Innate Pharma, Sorrento Therapeutics, GlaxoSmithKline, GITR, Inc”.
|Report Attributes||Report Details|
|Report Title||Immune Checkpoint Inhibitors Market Research Report|
|By Type||PD-1/PD-L1, CTLA-4|
|By Application||Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, Other|
|By Companies||Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, NewLink Genetics, ArGEN-X, Seattle Genetics, Pfizer, MacroGenics, Celldex Therapeutics, CureTech, Immutep, Innate Pharma, Sorrento Therapeutics, GlaxoSmithKline, GITR, Inc|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||240|
|Number of Tables & Figures||168|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type PD-1/PD-L1, CTLA-4 and By Application Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, Other.
Some of the companies that are profiled in this report are:
Immune Checkpoint Inhibitors Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Immune Checkpoint Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Immune Checkpoint Inhibitors Market Report:
Some other reports from this category!